Business
Interim Results for the six months to 30 June 2025
Poolbeg Pharma PLC announced its unaudited interim results for the six months to 30 June 2025, highlighting a strong financial position with a cash balance of £10.0 million, which includes £4.865 million gross proceeds from an oversubscribed fundraise. This extends the cash runway into 2027, supporting key clinical milestones. The loss for the period amounted to £2.2 million, which comprised of R&D expenses of £0.5 million and administrative expenses of £2.0 million. The company's total equity stands at £11.932 million. Basic and diluted loss per share was (0.43)p. Intangible assets were valued at £1.662 million. Disclaimer*
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n\n\n \nPoolbeg Pharma plc\n \nInterim Results for the six months to 30 June 2025\n \n Well-funded with multiple upcoming clinical milestones\n \n29 September 2025 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2025.\nHighlights & Updates\n\n\n\n\n•\n\n\nCash balance of £10.0 million as at 30 June 2025, including £4.865 million gross proceeds raised as part of an oversubscribed and upsized fundraise\n\n\n\n\n•\n\n\nCash runway extended into 2027, supporting the delivery of multiple key clinical milestones\n\n\n\n\n•\n\n\nSpecialist blood cancer trials organisation Accelerating Clinical Trials Limited appointed to conduct POLB 001 Phase 2a trial, and supply of an approved bispecific antibody drug secured for the trial at no cost to the Company\n\n\n\n\n•\n\n\nTrial due to take place at The Christie NHS Foundation Trust and other leading UK specialist cancer centres, with interim data expected summer 2026\n\n\n\n\n•\n\n\nPOLB 001 granted Orphan Drug Designation by FDA as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (\"CRS\"), further validating POLB 001's scientific rationale and enhancing its commercial appeal\n\n\n\n\n•\n\n\nPositive data from an in vivo animal study in H1 2025 supported the use of POLB 001 to prevent CRS induced by T-cell engaging bispecific antibody therapies\n\n\n\n\n•\n\n\nProgress made towards commencement of oral GLP-1 proof of concept trial at University of Ulster, led by Prof Carel le Roux with up to 20 obese subjects, with topline data expected H1 2026\n\n\n\n\n•\n\n\nThe Company's pipeline programmes are in areas of significant interest to the pharmaceutical industry and as such, Poolbeg anticipates strong potential for partnering on positive data from the forthcoming clinical trials\n\n\n\n\n \nJeremy Skillington, PhD, Chief Executive Officer of Poolbeg, commented: \"We have made excellent progress this year and have entered a catalyst-rich period for Poolbeg. Preparations for the POLB 001 Phase 2a trial are well advanced, with the approved bispecific antibody secured at no cost to the Company. The d...